Liana Nobre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Liana Nobre has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Cynthia Hawkins
Division of Pathology, The Hospital for Sick Children, Toronto, Canada
29 shared publications - Uri Tabori
Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada
29 shared publications - Michal Zapotocky
Prague Brain Tumor Research Group, Second Faculty of Medicine, Charles University Prague and Motol and Homolka University Hospital, Prague, Czech Republic
28 shared publications - Birgit Ertl-Wagner
The Hospital for Sick Children
27 shared publications - Eric Bouffet
Division of Haematology/Oncology Hospital for Sick Children Toronto Ontario Canada
27 shared publications - Vijay Ramaswamy
Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Canada
27 shared publications
Latest Publications
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (11) , 2053-2067
Cost-Effectiveness of Dabrafenib Plus Trametinib Versus Standard Chemotherapy in BRAFV600E -Mutant Pediatric Low-Grade Glioma
PURPOSE: Dabrafenib in combination with trametinib (Dab-Tram) is increasingly regarded as an emerging standard of care for patients with BRAFV600E -mutant pediatric low-grade glioma (PLGG) internationally. Given the high costs of these targeted therapies, we estimated the cost-effectiveness of Dab-Tram versus standard chemotherapy in BRAFV600E -mutant PLGG. METHODS: We constructed a microsimulation model to simulate a cohort of patients with BRAFV600E-mutant PLGG from initiation of first-line systemic therapy to death. Clinical efficacy was extrapolated from the TADPOLE phase II clinical trial (ClinicalTrials.gov identifier: NCT02684058 ). Utilities and long-term risks of late effects were sourced from published literature. Costs were extracted from Canadian data sources. Cost-effectiveness was calculated from a Canadian public health care payer perspective at a discount rate of 1.5%, expressed in 2024 Canadian dollars. The base case modeled lifetime Dab-Tram treatment, to reflect clinical paradigms of indefinite Dab-Tram therapy. Sensitivity analyses exploring minimum treatment durations, price of Dab-Tram, discount rate, use of radiation, and incorporating real-world data were conducted. RESULTS: Dab-Tram was associated with a 2.21 quality-adjusted life-year (QALY) gain at an incremental cost of $554,769 Canadian dollars (CAD) compared with standard chemotherapy. The base case incremental cost-effectiveness ratio (ICER) was $251,027 CAD/QALY. Two-year Dab-Tram resulted in an ICER of $44,740 CAD/QALY, while ICERs across other scenarios ranged from $26,013 CAD to $410,196 CAD/QALY. Results were sensitive to assumed survival distributions and use of independent assessment of TADPOLE outcomes. CONCLUSION: Our findings demonstrate that the cost-effectiveness of Dab-Tram is sensitive to price and duration of treatment, with uncertainty related to clinical effectiveness over the life course and optimal treatment duration. In the context of clinical paradigms favoring indefinite treatment, Dab-Tram is unlikely to prove cost-effective at the present price and would require a price reduction to facilitate sustained access.
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (11) , 2053-2067
Cost-Effectiveness of Dabrafenib Plus Trametinib Versus Standard Chemotherapy in BRAFV600E -Mutant Pediatric Low-Grade Glioma
PURPOSE: Dabrafenib in combination with trametinib (Dab-Tram) is increasingly regarded as an emerging standard of care for patients with BRAFV600E -mutant pediatric low-grade glioma (PLGG) internationally. Given the high costs of these targeted therapies, we estimated the cost-effectiveness of Dab-Tram versus standard chemotherapy in BRAFV600E -mutant PLGG. METHODS: We constructed a microsimulation model to simulate a cohort of patients with BRAFV600E-mutant PLGG from initiation of first-line systemic therapy to death. Clinical efficacy was extrapolated from the TADPOLE phase II clinical trial (ClinicalTrials.gov identifier: NCT02684058 ). Utilities and long-term risks of late effects were sourced from published literature. Costs were extracted from Canadian data sources. Cost-effectiveness was calculated from a Canadian public health care payer perspective at a discount rate of 1.5%, expressed in 2024 Canadian dollars. The base case modeled lifetime Dab-Tram treatment, to reflect clinical paradigms of indefinite Dab-Tram therapy. Sensitivity analyses exploring minimum treatment durations, price of Dab-Tram, discount rate, use of radiation, and incorporating real-world data were conducted. RESULTS: Dab-Tram was associated with a 2.21 quality-adjusted life-year (QALY) gain at an incremental cost of $554,769 Canadian dollars (CAD) compared with standard chemotherapy. The base case incremental cost-effectiveness ratio (ICER) was $251,027 CAD/QALY. Two-year Dab-Tram resulted in an ICER of $44,740 CAD/QALY, while ICERs across other scenarios ranged from $26,013 CAD to $410,196 CAD/QALY. Results were sensitive to assumed survival distributions and use of independent assessment of TADPOLE outcomes. CONCLUSION: Our findings demonstrate that the cost-effectiveness of Dab-Tram is sensitive to price and duration of treatment, with uncertainty related to clinical effectiveness over the life course and optimal treatment duration. In the context of clinical paradigms favoring indefinite treatment, Dab-Tram is unlikely to prove cost-effective at the present price and would require a price reduction to facilitate sustained access.
- Open Access
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Demographics and details of treatment in patients who continued ICI progression (n=38)
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Demographics and details of treatment in patients who continued ICI progression (n=38)
- Open Access
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Figure 4 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Patients treated with nivolumab and trametinib (n = 5). A, Objective responses in bifocal glioblastoma progressing on nivolumab. B, Swimmer's plot summarizing events in each patient. C, The patient progressing at primary and distant sites on nivolumab had complete response on being simultaneously treated with radiation and addition of trametinib to nivolumab. T-cell receptor (TCR) clonotype analysis shows an initial increase in TCRB after starting on nivolumab, and invigoration of response at salvage treatment postprogression. This was observed both in terms of increased absolute clonal counts after adding trametinib, as well as clonal selection, plausibly for more tumor-specific TCR clones (as shown by the colored bars), as this correlated with the response seen in radiology. MEK-i, MEK inhibitor.
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Patients treated with nivolumab and trametinib (n = 5). A, Objective responses in bifocal glioblastoma progressing on nivolumab. B, Swimmer's plot summarizing events in each patient. C, The patient progressing at primary and distant sites on nivolumab had complete response on being simultaneously treated with radiation and addition of trametinib to nivolumab. T-cell receptor (TCR) clonotype analysis shows an initial increase in TCRB after starting on nivolumab, and invigoration of response at salvage treatment postprogression. This was observed both in terms of increased absolute clonal counts after adding trametinib, as well as clonal selection, plausibly for more tumor-specific TCR clones (as shown by the colored bars), as this correlated with the response seen in radiology. MEK-i, MEK inhibitor.
- Open Access
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Figure 4 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Patients treated with nivolumab and trametinib (n = 5). A, Objective responses in bifocal glioblastoma progressing on nivolumab. B, Swimmer's plot summarizing events in each patient. C, The patient progressing at primary and distant sites on nivolumab had complete response on being simultaneously treated with radiation and addition of trametinib to nivolumab. T-cell receptor (TCR) clonotype analysis shows an initial increase in TCRB after starting on nivolumab, and invigoration of response at salvage treatment postprogression. This was observed both in terms of increased absolute clonal counts after adding trametinib, as well as clonal selection, plausibly for more tumor-specific TCR clones (as shown by the colored bars), as this correlated with the response seen in radiology. MEK-i, MEK inhibitor.
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Patients treated with nivolumab and trametinib (n = 5). A, Objective responses in bifocal glioblastoma progressing on nivolumab. B, Swimmer's plot summarizing events in each patient. C, The patient progressing at primary and distant sites on nivolumab had complete response on being simultaneously treated with radiation and addition of trametinib to nivolumab. T-cell receptor (TCR) clonotype analysis shows an initial increase in TCRB after starting on nivolumab, and invigoration of response at salvage treatment postprogression. This was observed both in terms of increased absolute clonal counts after adding trametinib, as well as clonal selection, plausibly for more tumor-specific TCR clones (as shown by the colored bars), as this correlated with the response seen in radiology. MEK-i, MEK inhibitor.
- Open Access
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Figure 6 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Delayed response after initial progression on continued anti–PD-1 monotherapy. A, Delayed response after initial progression on nivolumab monotherapy. B, Cyst decompression and biopsy at progression showed a more mitotically active and higher grade tumor with higher TMB and increased CD8 T-cell infiltration. C, Mutation overlap showed minimal overlap of the somatic mutational spectrum between the two time points (200X magnification; scale bars represent 50 µm). D, Normalized expression counts of immune markers before initiation and after progression on anti–PD-1 monotherapy using the NanoString platform (100X magnification, scale bars represent 100 µm; Methods).
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Delayed response after initial progression on continued anti–PD-1 monotherapy. A, Delayed response after initial progression on nivolumab monotherapy. B, Cyst decompression and biopsy at progression showed a more mitotically active and higher grade tumor with higher TMB and increased CD8 T-cell infiltration. C, Mutation overlap showed minimal overlap of the somatic mutational spectrum between the two time points (200X magnification; scale bars represent 50 µm). D, Normalized expression counts of immune markers before initiation and after progression on anti–PD-1 monotherapy using the NanoString platform (100X magnification, scale bars represent 100 µm; Methods).
- Open Access
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Figure 2 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Genomic features of patients with RRD-HGG treated with salvage therapies (n = 38). A, Onco-plot summarizing clinical and genomic features of patients who progressed on anti–PD-1 monotherapy and continued ICI treatment. B, Impact of TMB on survival. C, Impact of genomic MSI as measured by the tumor MMRDness score on survival (Methods).
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Genomic features of patients with RRD-HGG treated with salvage therapies (n = 38). A, Onco-plot summarizing clinical and genomic features of patients who progressed on anti–PD-1 monotherapy and continued ICI treatment. B, Impact of TMB on survival. C, Impact of genomic MSI as measured by the tumor MMRDness score on survival (Methods).
- Open Access
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Baseline characteristics of patients with RRD high-grade gliomas treated with immune-checkpoint inhibition (ICI) (n=75)
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Baseline characteristics of patients with RRD high-grade gliomas treated with immune-checkpoint inhibition (ICI) (n=75)
- Open Access
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S5 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Supplementary Figures S1 to S5, with each figure followed by its corresponding legend in the next page
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S5 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Supplementary Figures S1 to S5, with each figure followed by its corresponding legend in the next page
- Open Access
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S5 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Supplementary Figures S1 to S5, with each figure followed by its corresponding legend in the next page
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S5 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Supplementary Figures S1 to S5, with each figure followed by its corresponding legend in the next page
- Open Access
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Figure 6 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Delayed response after initial progression on continued anti–PD-1 monotherapy. A, Delayed response after initial progression on nivolumab monotherapy. B, Cyst decompression and biopsy at progression showed a more mitotically active and higher grade tumor with higher TMB and increased CD8 T-cell infiltration. C, Mutation overlap showed minimal overlap of the somatic mutational spectrum between the two time points (200X magnification; scale bars represent 50 µm). D, Normalized expression counts of immune markers before initiation and after progression on anti–PD-1 monotherapy using the NanoString platform (100X magnification, scale bars represent 100 µm; Methods).
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Delayed response after initial progression on continued anti–PD-1 monotherapy. A, Delayed response after initial progression on nivolumab monotherapy. B, Cyst decompression and biopsy at progression showed a more mitotically active and higher grade tumor with higher TMB and increased CD8 T-cell infiltration. C, Mutation overlap showed minimal overlap of the somatic mutational spectrum between the two time points (200X magnification; scale bars represent 50 µm). D, Normalized expression counts of immune markers before initiation and after progression on anti–PD-1 monotherapy using the NanoString platform (100X magnification, scale bars represent 100 µm; Methods).